Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a Cochrane Review and network meta-analysis

To assess the effects of bisphosphonates and RANK-ligand (RANKL)-inhibitors for supportive treatment in prostate cancer with bone metastases and to generate a clinically meaningful treatment ranking according to their safety and efficacy.

This is a protocol.

Share/Save
Health topics: